Malignancies in Systemic Rheumatic Diseases: A Mini Review

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2023 Mar 17

PMID 36926334

Authors

Zhe Geng

Cong Ye

Xiaojian Zhu

Affiliations

Soon will be listed here.

Abstract

There is an increased risk of malignancies in patients with many systemic rheumatic diseases, which negatively impact on their quality of life. The risk and types of malignancies can differ by the type of rheumatic diseases. Possible mechanisms linking them are dynamic and complicated, including chronic inflammation and damage in rheumatic disease, inability to clear oncogenic infections, shared etiology and some anti-rheumatic therapies. Although certain disease-modifying anti-rheumatic drugs (DMARDs) have been proved to be potentially carcinogenic, the majority of them were not associated with increased risk of most malignancies in patients with systemic rheumatic diseases.

Citing Articles

Practical Use of Ultrasound in Modern Rheumatology-From A to Z.

Sapundzhieva T, Sapundzhiev L, Batalov A Life (Basel). 2024; 14(9).

PMID: 39337990 PMC: 11433054. DOI: 10.3390/life14091208.

References

Zhong H, Liu S, Wang Y, Xu D, Li M, Zhao Y . Primary Sjögren's syndrome is associated with increased risk of malignancies besides lymphoma: A systematic review and meta-analysis. Autoimmun Rev. 2022; 21(5):103084. DOI: 10.1016/j.autrev.2022.103084. View

Bernatsky S, Clarke A, Niaki O, Labrecque J, Schanberg L, Silverman E . Malignancy in Pediatric-onset Systemic Lupus Erythematosus. J Rheumatol. 2017; 44(10):1484-1486. PMC: 5657309. DOI: 10.3899/jrheum.170179. View

Oldroyd A, Sergeant J, New P, McHugh N, Betteridge Z, Lamb J . The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis. Rheumatology (Oxford). 2018; 58(4):650-655. PMC: 6434375. DOI: 10.1093/rheumatology/key357. View

Wang X, Lin Y . Tumor necrosis factor and cancer, buddies or foes?. Acta Pharmacol Sin. 2008; 29(11):1275-88. PMC: 2631033. DOI: 10.1111/j.1745-7254.2008.00889.x. View

Dolcino M, Pelosi A, Fiore P, Patuzzo G, Tinazzi E, Lunardi C . Gene Profiling in Patients with Systemic Sclerosis Reveals the Presence of Oncogenic Gene Signatures. Front Immunol. 2018; 9:449. PMC: 5845728. DOI: 10.3389/fimmu.2018.00449. View

Nocturne G, Mariette X . Sjögren Syndrome-associated lymphomas: an update on pathogenesis and management. Br J Haematol. 2014; 168(3):317-27. DOI: 10.1111/bjh.13192. View

Azher S, Azami O, Amato C, McCullough M, Celentano A, Cirillo N . The Non-Conventional Effects of Glucocorticoids in Cancer. J Cell Physiol. 2016; 231(11):2368-73. DOI: 10.1002/jcp.25408. View

Raaschou P, Simard J, Asker Hagelberg C, Askling J . Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden. BMJ. 2016; 352:i262. PMC: 4730989. DOI: 10.1136/bmj.i262. View

Lafyatis R, Valenzi E . Assessment of disease outcome measures in systemic sclerosis. Nat Rev Rheumatol. 2022; 18(9):527-541. DOI: 10.1038/s41584-022-00803-6. View

10.

Jankowski J, De Caestecker J, Love S, Reilly G, Watson P, Sanders S . Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial. Lancet. 2018; 392(10145):400-408. PMC: 6083438. DOI: 10.1016/S0140-6736(18)31388-6. View

11.

Joseph C, Darrah E, Shah A, Skora A, Casciola-Rosen L, Wigley F . Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science. 2013; 343(6167):152-7. PMC: 4038033. DOI: 10.1126/science.1246886. View

12.

Emadi A, Jones R, Brodsky R . Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol. 2009; 6(11):638-47. DOI: 10.1038/nrclinonc.2009.146. View

13.

DeWane M, Waldman R, Lu J . Dermatomyositis: Clinical features and pathogenesis. J Am Acad Dermatol. 2019; 82(2):267-281. DOI: 10.1016/j.jaad.2019.06.1309. View

14.

Huss V, Bower H, Wadstrom H, Frisell T, Askling J . Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice. Rheumatology (Oxford). 2021; 61(5):1810-1818. PMC: 9071561. DOI: 10.1093/rheumatology/keab570. View

15.

Bernatsky S, Ramsey-Goldman R, Urowitz M, Hanly J, Gordon C, Petri M . Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. Arthritis Care Res (Hoboken). 2020; 73(12):1789-1795. PMC: 7892637. DOI: 10.1002/acr.24425. View

16.

Maria A, Partouche L, Goulabchand R, Riviere S, Rozier P, Bourgier C . Intriguing Relationships Between Cancer and Systemic Sclerosis: Role of the Immune System and Other Contributors. Front Immunol. 2019; 9:3112. PMC: 6335319. DOI: 10.3389/fimmu.2018.03112. View

17.

Rubbert-Roth A, Enejosa J, Pangan A, Haraoui B, Rischmueller M, Khan N . Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis. N Engl J Med. 2020; 383(16):1511-1521. DOI: 10.1056/NEJMoa2008250. View

18.

de Germay S, Bagheri H, Despas F, Rousseau V, Montastruc F . Abatacept in rheumatoid arthritis and the risk of cancer: a world observational post-marketing study. Rheumatology (Oxford). 2019; 59(9):2360-2367. DOI: 10.1093/rheumatology/kez604. View

19.

Oldroyd A, Allard A, Callen J, Chinoy H, Chung L, Fiorentino D . A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies. Rheumatology (Oxford). 2021; 60(6):2615-2628. PMC: 8213426. DOI: 10.1093/rheumatology/keab166. View

20.

Tyndall A, Bannert B, Vonk M, Airo P, Cozzi F, Carreira P . Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010; 69(10):1809-15. DOI: 10.1136/ard.2009.114264. View